From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …

Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …

Assessment of cell free DNA (cfDNA) and RNA (cfRNA), circulating tumor cells (CTC) and
extracellular vesicles (EV) in blood or other bodily fluids can enable early cancer detection …

Next-generation sequencing (NGS) provides a broad investigation of the genome, and it is
being readily applied for the diagnosis of disease-associated genetic features. However, the …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

Few neoplastic diseases have undergone a transformation in a relatively short period like
chronic myeloid leukemia (CML) has in the last few years. In 1960, CML was the first cancer …

Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …

In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …

RNA is a tool used in many fields, from molecular and cellular biology to medicine and
nanotechnology. For most of these uses, the integrity of RNA is required and must be …

Monitoring BCR-ABL1 fusion transcripts by real-time quantitative RT-PCR has become an
important clinical test for the management of patients with chronic myeloid leukemia …